ArticleCurrent neuropharmacology2026

Efgartigimod in Very-Late-Onset Generalized Myasthenia Gravis: A Real-World Study on Effectiveness and Safety.

Chi Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.